ABILIFY MyCIte - The First FDA approved Digital Medicine

抄録

Otsuka and Proteus Digital Health developed the first digital medicine "Abilify MyCite" that can measure medication adherence. It embeds a very small sensor developed by Proteus into an antipsychotic Abilify tablet marketed by Otsuka. When a patient swallows tablets, a chip emits a signal in the stomach and it is captured by a small patch which sticks to the patient's abdomen and this is recorded. The patch transmits adherence information to the patient's smartphone as well as capturing activity and rest from sensors on the patch. The transmitted information is captured on both the patient's phone as well as shared with healthcare professionals, caregivers and families with the patients' consent. Based on this information, healthcare professionals can measure the condition of the patient and assess the risk if there is a sign of recurrence such as poor adherence or abnormal sleep pattern, then take the appropriate intervention.